Remedy offers docs (and advertisers) a platform for direct communication with patients

Share this article:

Remedy Health is looking to close the loop—and sell advertising off of it—with the launch of a service letting doctors, pharmacies and other healthcare providers send topical health content to their patients.

The service is called Patient Health Services, and the company boasts that it's achieved a 45% open rate in pilot.

“In the world of Big Data, this is truly data targeting combined with content creation,” says Jim Curtis, chief revenue officer at the publisher. “This allows doctors to provide more information about whatever it is that they're treating or general health information the patient needs to know, with really credible content from Remedy Health. No one's doing this in a national way. We've aggregated so much data that we can target advertisers.”

The company, which bought HealthCentral a year ago, has assembled a database of 4 million patients, along with a network of 500 practices whose physicians can use the program to send, for example, information about a meal plan to a patient recently diagnosed with diabetes. The publisher plans to add an appointment reminder function sometime in the second quarter of 2013.

Early advertisers include Novartis (for Diovan) and Allergan (for Restasis), along with consumer wellness brands like Eggland's Best.

“We can include you in a physician-patient conversation specific to your product,” says Curtis. “Patients love it. The open rates are way above average.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...